HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Picks At Industry Self-Regulation Group Measuring Flosser Market By Units, Not Sales

Appeals NAD Decision On Oral-B Marketer P&G’s Challenge Of Plackers ‘#1 Brand’ Claim

Executive Summary

NAD says “equivalized” sales data Perrigo submitted to support claim didn’t provide an accurate measure of flosser product category; instead, “un-equivalized” data P&G submitted were accurate measure. Perrigo counters that the decision conflated separate product categories as well as dismissed appropriate data.

You may also be interested in...



Floss By Any Other Name Would Sell In Same Category – BBB National Programs Appeals Panel

NARB panel concluded #1 claims challenged by Oral-B floss products marketer P&G aren’t supported by acceptable evidence that the type of product the claim referenced – flossers  – “is recognized as a consumer-relevant category."

Ranir Oral Care Deal Could Brighten Perrigo's Turnaround Chances

Ranir has a portfolio of more than 300 oral care solutions including power toothbrushes and heads, whitening strips, manual toothbrushes, floss, dentures and travel kits that it provides to retailers and other distributors in more than 50 countries. Adding Ranir, says Perrigo CEO Murray Kessler, "illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories."

Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers

“Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFl isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.

 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel